Electra Therapeutics, Inc. Common stock (ETRA) - Total Liabilities
Based on the latest financial reports, Electra Therapeutics, Inc. Common stock (ETRA) has total liabilities worth $133.27 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Electra Therapeutics, Inc. Common stock defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Electra Therapeutics, Inc. Common stock - Total Liabilities Trend (2024–2025)
This chart illustrates how Electra Therapeutics, Inc. Common stock's total liabilities have evolved over time, based on quarterly financial data. Check Electra Therapeutics, Inc. Common stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Electra Therapeutics, Inc. Common stock Competitors by Total Liabilities
The table below lists competitors of Electra Therapeutics, Inc. Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Prime Medicine, Inc. Common Stock
NASDAQ:PRME
|
USA | $209.23 Million |
|
WCE Holdings Bhd
KLSE:3565
|
Malaysia | RM7.71 Billion |
|
Northfield Bancorp Inc
NASDAQ:NFBK
|
USA | $5.06 Billion |
|
Andes Technology Corp
TW:6533
|
Taiwan | NT$1.78 Billion |
|
Aris Water Solutions Inc
NYSE:ARIS
|
USA | $689.21 Million |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$732.53 Million |
|
Eastern Polymer Group Public Company Limited
BK:EPG
|
Thailand | ฿7.38 Billion |
|
Fujian Minfa Aluminium Co Ltd
SHE:002578
|
China | CN¥889.48 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Electra Therapeutics, Inc. Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ETRA total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -4.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Electra Therapeutics, Inc. Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Electra Therapeutics, Inc. Common stock (2024–2025)
The table below shows the annual total liabilities of Electra Therapeutics, Inc. Common stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $129.69 Million | +5.72% |
| 2024-12-31 | $122.68 Million | -- |
About Electra Therapeutics, Inc. Common stock
Electra Therapeutics, Inc. is a clinical-stage biotechnology company. It develops therapies that target signal regulatory proteins for the treatment of novel targets for diseases in immunology and cancer. Its product, ELA026, is a monoclonal antibody that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, enabling medical professio… Read more